Current Evidence from Phase III Clinical Trials of Selenium Supplementation in Critically Ill Patients: Why Should We Bother?

Publisher： Bentham Science Publishers

E-ISSN： 1875-5607|7|7|693-699

ISSN： 1389-5575

Source： Mini Reviews in Medicinal Chemistry, Vol.7, Iss.7, 2007-07, pp. : 693-699

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Why should We Bother? Ethical and Social Issues in Individualized Medicine

By  

Current Drug Targets, Vol. 7, Iss. 12, 2006-01 ,pp. : 1721-1727

Bentham Science Publishers

Access to resources Recommend Favorite

Uncertainty in the Translation of Preclinical Experiments to Clinical Trials. Why do Most Phase III Clinical Trials Fail?

By  

Current Gene Therapy, Vol. 9, Iss. 5, 2009-01 ,pp. : 368-374

Bentham Science Publishers

Access to resources Recommend Favorite

Clinical Potential of Insulin Therapy in Critically Ill Patients

By Mesotten D.   Berghe G.V.d.  

Drugs, Vol. 63, Iss. 7, 2003-01 ,pp. : 625-636

Adis International

Access to resources Recommend Favorite

HIV in IDUs: should we bother?

By Panda S.  

The International Journal of Drug Policy, Vol. 14, Iss. 1, 2003-02 ,pp. : 83-85

Elsevier

Access to resources Recommend Favorite

Glutamine supplementation: beneficial in critically ill patients?

By  

Inpharma, Vol. 1, Iss. 1363, 2002-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite